Literature DB >> 16156109

Tissue microarrays.

Ronald Simon1, Martina Mirlacher, Guido Sauter.   

Abstract

New high-throughput screening technologies have led to the identification of hundreds of genes with potential roles in cancer or other diseases. For evaluation of promising candidate genes, however, in-situ analysis of high numbers of clinical tissue samples is mandatory. The tissue microarray (TMA) technology greatly facilitates such analysis. In this method minute tissue samples (0.6 mm in diameter) from up to 1000 different tissues can be analyzed on one microscope glass slide. All in-situ methods suitable for histological studies can be applied to TMAs without major changes in protocols, including immunohistochemistry, fluorescence in-situ hybridization, or RNA in-situ hybridization. Because all tissues are analyzed simultaneously with the same batch of reagents, TMA studies provide an unprecedented degree of standardization, speed, and cost efficiency.

Entities:  

Mesh:

Year:  2005        PMID: 16156109     DOI: 10.1385/1-59259-923-0:257

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  27 in total

1.  Somatic BRCA1-associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma.

Authors:  Heike Loeser; Dirk Waldschmidt; Fabian Kuetting; Simon Schallenberg; Thomas Zander; Elfriede Bollschweiler; Arnulf Hoelscher; Katharina Weckermann; Patrick Plum; Hakan Alakus; Reinhard Buettner; Alexander Quaas
Journal:  Mol Clin Oncol       Date:  2017-06-08

2.  βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma.

Authors:  Alexander Quaas; Amir-Hossein Rahvar; Christoph Burdelski; Christina Koop; Christian Eichelberg; Michael Rink; Roland Dahlem; Thorsten Schlomm; Maria Christina Tsourlakis; Ronald Simon; Sarah Minner; Guido Sauter; Stefan Steurer
Journal:  World J Urol       Date:  2014-12-21       Impact factor: 4.226

3.  Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays.

Authors:  Phillip R Stahl; Jessica Schnellert; Christina Koop; Ronald Simon; Andreas Marx; Jakob R Izbicki; Guido Sauter; Alexander Quaas
Journal:  Pathol Oncol Res       Date:  2015-05-31       Impact factor: 3.201

4.  Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.

Authors:  Patrick Sven Plum; Dita Ulase; Elfriede Bollschweiler; Seung-Hun Chon; Felix Berlth; Thomas Zander; Hakan Alakus; Arnulf H Hölscher; Christiane J Bruns; Simon Schallenberg; Alexander Quaas; Heike Loeser
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-04       Impact factor: 4.553

5.  Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.

Authors:  Sylvia Stadlmann; Uwe Gueth; Edward Wight; Leoni A Kunz-Schughart; Arndt Hartmann; Gad Singer
Journal:  J Clin Pathol       Date:  2006-05-12       Impact factor: 3.411

6.  AMACR expression in colorectal cancer is associated with left-sided tumor localization.

Authors:  Andreas Marx; Philipp Simon; Ronald Simon; Martina Mirlacher; Jakob R Izbicki; Emre Yekebas; Jussuf T Kaifi; Luigi Terracciano; Guido Sauter
Journal:  Virchows Arch       Date:  2008-08-19       Impact factor: 4.064

7.  Automatic tumor-stroma separation in fluorescence TMAs enables the quantitative high-throughput analysis of multiple cancer biomarkers.

Authors:  Bernd Lahrmann; Niels Halama; Hans-Peter Sinn; Peter Schirmacher; Dirk Jaeger; Niels Grabe
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

8.  VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.

Authors:  Maria Christina Tsourlakis; Puya Khosrawi; Philipp Weigand; Martina Kluth; Claudia Hube-Magg; Sarah Minner; Christina Koop; Markus Graefen; Hans Heinzer; Corinna Wittmer; Guido Sauter; Till Krech; Waldemar Wilczak; Hartwig Huland; Ronald Simon; Thorsten Schlomm; Stefan Steurer
Journal:  Int J Mol Sci       Date:  2015-04-16       Impact factor: 5.923

9.  Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.

Authors:  Heike Loeser; Dirk Waldschmidt; Fabian Kuetting; Carina Heydt; Thomas Zander; Patrick Plum; Hakan Alakus; Reinhard Buettner; Alexander Quaas
Journal:  Mol Clin Oncol       Date:  2017-03-14

10.  Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Authors:  Doris Helbig; Michaela Angelika Ihle; Katharina Pütz; Iliana Tantcheva-Poor; Cornelia Mauch; Reinhard Büttner; Alexander Quaas
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.